Daily biotech intelligence: FDA actions, drug recalls, and recent research.
Unknown — Approved Sponsor: IPCA LABS LTD · Application type: ORIG · Date: 20260501
JUNIOR STRENGTH ADVIL (IBUPROFEN) — Approved Sponsor: HALEON US HOLDINGS · Application type: SUPPL · Date: 20140213
AUVELITY (DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE) — Approved Sponsor: AXSOME · Application type: SUPPL · Date: 20260430 · Priority: STANDARD
XPOVIO (SELINEXOR) — Approved Sponsor: KARYOPHARM THERAPS · Application type: SUPPL · Date: 20201218 · Priority: STANDARD
OMEPRAZOLE — Approved Sponsor: DR REDDYS · Application type: SUPPL · Date: 20260429 · Priority: UNKNOWN
REXULTI (BREXPIPRAZOLE) — Approved Sponsor: OTSUKA · Application type: ORIG · Date: 20150710 · Priority: STANDARD
DEXMEDETOMIDINE — Approved Sponsor: HQ SPCLT PHARMA · Application type: SUPPL · Date: 20210607 · Priority: N/A
LEUPROLIDE ACETATE — Approved Sponsor: SOMERSET THERAPS LLC · Application type: ORIG · Date: 20210813 · Priority: STANDARD
The Harvard Drug Group LLC [Class II] — 20260429 Product: Omega-3-Acid, Ethyl Esters, Capsules, USP, 1 gram, 50 capsules (5 x 10 unit dose blister cards) per Reason: Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.
B BRAUN MEDICAL INC [Class II] — 20260429 Product: DEXTROSE INJECTION USP, 70%, 2000 mL bags, Rx only, Sterile, B. Braun Medical Inc., Bethlehem, PA 18 Reason: Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.
Leading Pharma, LLC [Class II] — 20260429 Product: Furosemide Tablets, USP, 80 mg, 100 Tablets bottles, Rx only, Manufactured by: Leading Pharma, LLC, Reason: CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.
Premier Dental Products Co [Class III] — 20260429 Product: Premier, Monsel's, Ferric Subsulfate Solution, 8 mL bottles, Rx only, Manufacturer: Premier Medical Reason: Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (202
B BRAUN MEDICAL INC [Class II] — 20260429 Product: LACTATED RINGER'S IRRIGATION, 3000 mL bags, Sterile, Ex only, B. Braun Medical Inc., Bethlehem, PA 1 Reason: Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.
Sushovan Majhi, Atish Mitra, Žiga Virk · 2026-05-05 · cs.LG · math.AT
We introduce PALACE (Persistence Adaptive-Landmark Analytic Classification Engine), the data-adaptive companion to PLACE, paying a small cross-validation tier on three knobs (budget, radii, bandwidth; $\leq 5$ choices each). A cover-theoretic core (Lebesgue-number criterion on the landmark cover) yields four closed-form guarantees. (i) A structural
Sebastian Wind, Tri-Thien Nguyen, Jeta Sopa · 2026-05-05 · cs.CL · cs.AI
Clinical LLMs are often scaled by increasing model size, context length, retrieval complexity, or inference-time compute, with the implicit expectation that higher accuracy implies safer behavior. This assumption is incomplete in medicine, where a few confident, high-risk, or evidence-contradicting errors can matter more than average benchmark perf
Evangelos Ntavelis, Sean Wu, Mohamad Shahbazi · 2026-05-05 · cs.CV · cs.LG
We propose HeadsUp, a scalable feed-forward method for reconstructing high-quality 3D Gaussian heads from large-scale multi-camera setups. Our method employs an efficient encoder-decoder architecture that compresses input views into a compact latent representation. This latent representation is then decoded into a set of UV-parameterized 3D Gaussia
Francisco M. Castro-Macías, Pablo Morales-Álvarez, Saifuddin Syed · 2026-05-05 · stat.ML · cs.LG
Sampling from unnormalized multimodal distributions with limited density evaluations remains a fundamental challenge in machine learning and natural sciences. Successful approaches construct a bridge between a tractable reference and the target distribution. Parallel Tempering (PT) serves as the gold standard, while recent diffusion-based approache
Adwaitt Pandya, Ozioma C. Oguine, Harita Bhargava · 2026-05-05 · cs.CV · cs.LG
A brain tumor is a medical disorder faced by individuals of all demographics. Medically, it is described as the spread of non-essential cells close to or throughout the brain. Symptoms of this ailment include headaches, seizures, and sensory changes. This research explores two main categories of brain tumors: benign and malignant. Benign spreads st
Aaron Havens, Brian Karrer, Neta Shaul · 2026-05-05 · cs.LG · cs.AI
Sampling from unnormalized densities is analogous to the generative modeling problem, but the target distribution is defined by a known energy function instead of data samples. Because evaluating the energy function is often costly, a primary challenge is to learn an efficient sampler. We introduce Flow Sampling, a framework built on diffusion mode
Zakarya Elmimouni, Fares Fourati, Mohamed-Slim Alouini · 2026-05-05 · cs.CV · cs.AI
Accurate school detection is essential for supporting education initiatives, including infrastructure planning and expanding internet connectivity to underserved areas. However, many regions around the world face challenges due to outdated, incomplete, or unavailable official records. Manual mapping efforts, while valuable, are labor-intensive and
Eszter Varga-Umbrich, Shikha Surana, Paul Duckworth · 2026-05-05 · cs.LG · physics.chem-ph
Training machine learning interatomic potentials (MLIPs) for reactive chemistry is often bottlenecked by the high cost of quantum chemical labels and the scarcity of transition state configurations in candidate pools. Active learning (AL) can mitigate these costs, but its effectiveness hinges on the acquisition rule. We investigate whether the late
Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it? (STAT News) The psychedelics field is getting what it has long wanted. Now it has to step up.
STAT+: OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations (STAT News) Policy recommendations in OpenAI's blueprint for unlocking AI’s potential to change health care are reasonable, but also self-serving, experts say.
STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field (STAT News) Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.
Opinion: Dr. Glaucomflecken wants to make a stink (STAT News) “They don’t want this kind of scrutiny”: Why Dr. Glaucomflecken is getting involved in protests over an Oregon hospital system’s emergency department.
Opinion: STAT+: Ambiguous loss: a peculiar kind of grief in dementia care (STAT News) Ambiguous loss is at the heart of the dementia illness experience.
STAT+: Did AI really beat doctors at diagnosis? (STAT News) In this edition of STAT Health Tech: A high-profile study on AI's diagnostic capabilities, role of telehealth in abortion access, and an Epic lawsuit.
STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing (STAT News) The pharma industry saw its reputation among patient groups inch up last year, a new survey finds, but concerns remain over access and pricing.
STAT+: A new attack on AMA’s billing codes (STAT News) A key GOP lawmaker is broadening the party's efforts to combat health care fraud.
STAT+: Are analysts too quick to gloss over Lilly’s liver case? (STAT News) Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more (STAT News) HHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressants
Viridian data lift prospects for thyroid eye disease drug (BioPharma Dive) Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
Vertex earnings get muted investor response (BioPharma Dive) While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
This briefing is compiled automatically from FDA public APIs (openFDA), arXiv, and industry RSS feeds (STAT News, Fierce Biotech, BioPharma Dive, Nature, Science News). Not investment advice. Verify all data before making any decisions.